{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:10:08Z","timestamp":1762431008693},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,4,24]],"date-time":"2015-04-24T00:00:00Z","timestamp":1429833600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s00535-015-1080-1","type":"journal-article","created":{"date-parts":[[2015,4,23]],"date-time":"2015-04-23T06:26:38Z","timestamp":1429770398000},"page":"63-70","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["The clinical features of patients with a Y93H variant of hepatitis C virus detected by a PCR invader assay"],"prefix":"10.1007","volume":"51","author":[{"given":"Toshiki","family":"Kan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Senju","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Kawabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michihito","family":"Murao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuji","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Shimazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Nakaoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Ohki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Takagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takamitsu","family":"Kurashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoki","family":"Takamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Yoshioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,4,24]]},"reference":[{"key":"1080_CR1","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S1473-3099(05)70216-4","volume":"5","author":"CW Shepard","year":"2005","unstructured":"Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5:558\u201367.","journal-title":"Lancet Infect Dis"},{"key":"1080_CR2","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1002\/hep.1840360707","volume":"36","author":"P Marcellin","year":"2002","unstructured":"Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology. 2002;36:S47\u201356.","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"1080_CR3","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/liv.12745","volume":"35","author":"T Asselah","year":"2015","unstructured":"Asselah T, Marcellin P. Optimal IFN-free therapy in treatment-naive patients with HCV genotype 1 infection. Liver Int. 2015;35(Suppl 1):56\u201364.","journal-title":"Liver Int"},{"key":"1080_CR4","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/j.1872-034X.2009.00548.x","volume":"39","author":"F Suzuki","year":"2009","unstructured":"Suzuki F, Akuta N, Suzuki Y, et al. Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP-424), pegylated interferon and ribavirin for 12\u00a0weeks. Hepatol Res. 2009;39:1056\u201363.","journal-title":"Hepatol Res"},{"issue":"Suppl 1","key":"1080_CR5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1478-3231.2011.02725.x","volume":"32","author":"MP Manns","year":"2012","unstructured":"Manns MP, Markova AA, Calle Serrano B, et al. Phase III results of boceprevir in treatment naive patients with chronic hepatitis C genotype 1. Liver Int. 2012;32(Suppl 1):27\u201331.","journal-title":"Liver Int"},{"key":"1080_CR6","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s00535-013-0875-1","volume":"49","author":"N Hayashi","year":"2014","unstructured":"Hayashi N, Seto C, Kato M, et al. Once-daily simeprevir (TMC435) with peginterferon\/ribavirin for treatment-naive hepatitis C genotype 1-infected patients in Japan: the DRAGON study. J Gastroenterol. 2014;49:138\u201347.","journal-title":"J Gastroenterol"},{"key":"1080_CR7","doi-asserted-by":"crossref","unstructured":"Hayashi N, Mobashery N, Izumi N. Vaniprevir plus peginterferon alfa-2a and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase II study. J Gastroenterol. 2015;50:238\u2013248.","DOI":"10.1007\/s00535-014-0979-2"},{"key":"1080_CR8","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/hep.27113","volume":"59","author":"H Kumada","year":"2014","unstructured":"Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014;59:2083\u201391.","journal-title":"Hepatology"},{"key":"1080_CR9","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889\u201398.","journal-title":"N Engl J Med"},{"key":"1080_CR10","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.jhep.2014.08.018","volume":"61","author":"T Asselah","year":"2014","unstructured":"Asselah T, Bruno S, Craxi A. HCV cirrhosis at the edge of decompensation: will paritaprevir with ritonavir, ombitasvir, dasabuvir, and ribavirin solve the need for treatment? J Hepatol. 2014;61:1430\u20133.","journal-title":"J Hepatol"},{"key":"1080_CR11","first-page":"267","volume-title":"Hepatitis C viruses: genomes and molecular biology","author":"Y He","year":"2006","unstructured":"He Y, Staschke KA, Tan SL. HCV NS5A: a multifunctional regulator of cellular pathways and virus replication. In: Tan SL, editor. Hepatitis C viruses: genomes and molecular biology. Wymondham: Horizon Bioscience; 2006. p. 267\u201392."},{"key":"1080_CR12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1056\/NEJM199601113340203","volume":"334","author":"N Enomoto","year":"1996","unstructured":"Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med. 1996;334:77\u201381.","journal-title":"N Engl J Med"},{"key":"1080_CR13","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/hep.22339","volume":"48","author":"A El-Shamy","year":"2008","unstructured":"El-Shamy A, Nagano-Fujii M, Sasase N, et al. Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon\/ribavirin combination therapy. Hepatology. 2008;48:38\u201347.","journal-title":"Hepatology"},{"key":"1080_CR14","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1128\/JCM.35.1.201-207.1997","volume":"35","author":"O Ohno","year":"1997","unstructured":"Ohno O, Mizokami M, Wu RR, et al. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol. 1997;35:201\u20137.","journal-title":"J Clin Microbiol"},{"key":"1080_CR15","doi-asserted-by":"crossref","first-page":"720","DOI":"10.2957\/kanzo.55.720","volume":"55","author":"K Tadokoro","year":"2014","unstructured":"Tadokoro K, Suzuki F, Kobayashi M, et al. Rapid and high sensitive detection of Y93H amino acid substitution in HCV NS5A region using the PCR-Invader assay. Kanzo. 2014;55:720\u20132.","journal-title":"Kanzo"},{"key":"1080_CR16","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.3748\/wjg.v20.i5.1289","volume":"20","author":"T Nishikawa","year":"2014","unstructured":"Nishikawa T, Hashimoto S, Kawabe N, et al. Factors correlating with acoustic radiation force impulse elastography in chronic hepatitis C. World J Gastroenterol. 2014;20:1289\u201397.","journal-title":"World J Gastroenterol"},{"key":"1080_CR17","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1159\/000086064","volume":"48","author":"N Akuta","year":"2005","unstructured":"Akuta N, Suzuki F, Sezaki H, et al. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology. 2005;48:372\u201380.","journal-title":"Intervirology"},{"key":"1080_CR18","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ng.449","volume":"41","author":"Y Tanaka","year":"2009","unstructured":"Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-\u03b1 and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105\u20139.","journal-title":"Nat Genet"},{"key":"1080_CR19","doi-asserted-by":"crossref","unstructured":"Itakura J, Kurosaki M, Takada H, et al. Naturally occurring, resistance-associated hepatitis C virus NS5A variants are linked to IL28B genotype and are sensitive to interferon-based therapy. Hepatol Res. 2015. doi: 10.1111\/hepr.12474 .","DOI":"10.1111\/hepr.12474"},{"key":"1080_CR20","doi-asserted-by":"crossref","first-page":"e112647","DOI":"10.1371\/journal.pone.0112647","volume":"9","author":"Y Uchida","year":"2014","unstructured":"Uchida Y, Kouyama J, Naiki K, et al. A novel simple assay system to quantify the percent HCV-RNA levels of NS5A Y93H mutant strains and Y93 wild-type strains relative to the total HCV-RNA levels to determine the indication for antiviral therapy with NS5A inhibitors. PLoS One. 2014;9:e112647.","journal-title":"PLoS One"},{"key":"1080_CR21","doi-asserted-by":"crossref","first-page":"E360","DOI":"10.1111\/hepr.12316","volume":"44","author":"M Miura","year":"2014","unstructured":"Miura M, Maekawa S, Sato M, et al. Deep sequencing analysis of variants resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection. Hepatol Res. 2014;44:E360\u20137.","journal-title":"Hepatol Res"},{"key":"1080_CR22","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","volume":"461","author":"D Ge","year":"2009","unstructured":"Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399\u2013401.","journal-title":"Nature"},{"key":"1080_CR23","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s00535-013-0918-7","volume":"49","author":"N Shimada","year":"2014","unstructured":"Shimada N, Toyoda H, Tsubota A, et al. Baseline factors and very early viral response (week 1) for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study. J Gastroenterol. 2014;49:1485\u201394.","journal-title":"J Gastroenterol"},{"key":"1080_CR24","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00535-010-0358-6","volume":"46","author":"K Chayama","year":"2011","unstructured":"Chayama K, Hayes CN, Yoshioka K, et al. Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis C. J Gastroenterol. 2011;46:545\u201355.","journal-title":"J Gastroenterol"},{"key":"1080_CR25","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1099\/vir.0.19513-0","volume":"85","author":"T Taguchi","year":"2004","unstructured":"Taguchi T, Nagano-Fujii M, Akutsu M, et al. Hepatitis C virus NS5A protein interacts with 2\u2032,5\u2032-oligoadenylate synthetase and inhibits antiviral activity of IFN in an IFN sensitivity-determining region-independent manner. J Gen Virol. 2004;85:959\u201369.","journal-title":"J Gen Virol"},{"key":"1080_CR26","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.bbrc.2004.04.052","volume":"318","author":"YW Choi","year":"2004","unstructured":"Choi YW, Tan YJ, Lim SG, et al. Proteomic approach identifies HSP27 as an interacting partner of the hepatitis C virus NS5A protein. Biochem Biophys Res Commun. 2004;318:514\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"1080_CR27","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1006\/viro.2001.1225","volume":"292","author":"ST Shi","year":"2002","unstructured":"Shi ST, Polyak SJ, Tu H, et al. Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins. Virology. 2002;292:198\u2013210.","journal-title":"Virology"},{"key":"1080_CR28","doi-asserted-by":"crossref","unstructured":"Cheng D, Zhang L, Yang G, et al. Hepatitis C virus NS5A drives a PTEN-PI3\u00a0K\/Akt feedback loop to support cell survival. Liver Int. 2014. doi: 10.1111\/liv.12733 .","DOI":"10.1111\/liv.12733"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-015-1080-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00535-015-1080-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-015-1080-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T06:47:31Z","timestamp":1598942851000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00535-015-1080-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,24]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["1080"],"URL":"https:\/\/doi.org\/10.1007\/s00535-015-1080-1","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,24]]}}}